pMHC Nanoparticle Compositions for Sustained Targeted Immunotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing immunotherapies for diseases involving improper immune function suffer from lack of targeting specificity and adverse side effects.
Innovation Solution
Development of a nanoparticle core complexed with disease-relevant antigen-MHC complexes (pMHCs) to expand and differentiate T cell populations, using a polyethylene glycol (PEG) linker and iron oxide nanoparticles, with specific pMHC densities and diameters for targeted immune therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional immunotherapies are administered to treat diseases involving improper immune function, then immune response is modulated, but off target effects and adverse side effects occur due to lack of targeting specificity
Solution Approach 1:
The therapy is segmented into targeted nanoparticle-delivered pMHC complexes that specifically engage antigen-specific T cells, separating the therapeutic effect from off-target immune modulation. This segmentation allows precise delivery of immune modulating activity only to relevant T cell populations expressing the specific T cell receptor for the pMHC complex.
Solution Approach 2:
The pMHC complex serves as an intermediary that bridges the therapeutic agent and the target T cells. The nanoparticle-pMHC complex acts as a mediator that specifically interacts with T cells bearing the cognate T cell receptor, enabling targeted immune modulation without affecting other immune cells. This intermediary mechanism provides intrinsic targeting specificity that eliminates the need for additional targeting moieties.
2Reliability
If nanoparticle complexes with pMHC are used to expand T cell populations, then targeted immune therapy is achieved, but complex manufacturing and characterization requirements arise
Solution Approach 1:
The nanoparticle-pMHC complex platform serves multiple functions simultaneously: it acts as a T cell expansion agent, a therapeutic agent for treating autoimmune diseases, and a diagnostic tool through its specific binding to antigen-specific T cells. This multi-functionality reduces the need for separate manufacturing processes for different therapeutic modalities.
Solution Approach 2:
The system allows adjustment of key parameters such as pMHC density on nanoparticle surface, nanoparticle size, and pMHC class (I or II) to optimize different therapeutic outcomes. These parameter changes enable tuning of T cell expansion efficiency and therapeutic potency without fundamentally changing the manufacturing approach, simplifying scale-up from preclinical to clinical production.
Data Source
Figure 1A
Figure 1B
Figure 2~3
AI summary
This disclosure provides compositions and methods for promoting the formation, expansion and recruitment of TR1 cells and/or B cells in an antigen-specific manner and treating diseases and disorders in a subject in need thereof.